Novavax, has announced its initial agreement to license its proprietary, recombinant virus-like-particle vaccine technology to ROVI Pharmaceuticals
PMLiVE archive subscribers only.
The full content of this article is available to PMLiVE archive subscribers. If you have a current subscription, please use the login box to the left. If you would like to find out more about the PMLiVE archive, please
click here.
